Drug Profile
Research programme: monoclonal antibody biosimilars - International Biotech Center Generium
Alternative Names: GNR-007; GNR-022; GNR-042; GNR-045Latest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator International Biotech Center Generium
- Developer International Biotechnology Center Generium
- Class Anti-infectives; Antineoplastics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported B-cell lymphoma; Paroxysmal nocturnal haemoglobinuria; Respiratory tract infections; Rheumatoid arthritis
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for preclinical development in B-cell lymphoma in Russia (Parenteral)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Paroxysmal-nocturnal-haemoglobinuria in Russia (Parenteral)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Respiratory-tract-infections in Russia (Parenteral)